News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
326,497 Results
Type
Article (16171)
Company Profile (297)
Press Release (310021)
Multimedia
Podcasts (86)
Webinars (12)
Section
Business (91881)
Career Advice (172)
Deals (16290)
Drug Delivery (39)
Drug Development (53946)
Employer Resources (31)
FDA (7004)
Job Trends (5584)
News (165815)
Policy (12364)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (979)
Accelerated approval (24)
Adcomms (14)
Allergies (106)
Alliances (26198)
ALS (149)
Alzheimer's disease (1164)
Antibody-drug conjugate (ADC) (318)
Approvals (7275)
Artificial intelligence (322)
Autoimmune disease (183)
Automation (9)
Bankruptcy (111)
Best Places to Work (4797)
BIOSECURE Act (6)
Biosimilars (131)
Biotechnology (232)
Bladder cancer (118)
Brain cancer (54)
Breast cancer (408)
Cancer (3638)
Cardiovascular disease (269)
Career advice (157)
Career pathing (8)
CAR-T (241)
CDC (7)
Cell therapy (628)
Cervical cancer (19)
Clinical research (47116)
Collaboration (1377)
Company closure (2)
Compensation (664)
Complete response letters (51)
COVID-19 (1203)
CRISPR (95)
C-suite (653)
Cystic fibrosis (114)
Data (5073)
Denatured (17)
Depression (115)
Diabetes (291)
Diagnostics (1873)
Digital health (15)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (232)
Drug pricing (50)
Drug shortages (3)
Duchenne muscular dystrophy (257)
Earnings (36694)
Editorial (28)
Employer branding (4)
Employer resources (29)
Events (56372)
Executive appointments (677)
FDA (9101)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (13)
Frontotemporal dementia (26)
Funding (1125)
Gene editing (199)
Generative AI (27)
Gene therapy (553)
GLP-1 (573)
Government (1287)
Grass and pollen (4)
Guidances (192)
Healthcare (7174)
HIV (27)
Huntington's disease (47)
IgA nephropathy (84)
Immunology and inflammation (213)
Immuno-oncology (60)
Indications (110)
Infectious disease (1345)
Inflammatory bowel disease (171)
Inflation Reduction Act (10)
Influenza (61)
Intellectual property (190)
Interviews (18)
IPO (8191)
IRA (13)
Job creations (1046)
Job search strategy (138)
JPM (43)
Kidney cancer (10)
Labor market (25)
Layoffs (251)
Leadership (10)
Legal (2155)
Liver cancer (52)
Longevity (19)
Lung cancer (495)
Lymphoma (280)
Machine learning (28)
Management (7)
Manufacturing (467)
MASH (144)
Medical device (3638)
Medtech (3658)
Mergers & acquisitions (8843)
Metabolic disorders (840)
mRNA (125)
Multiple sclerosis (121)
NASH (14)
Neurodegenerative disease (293)
Neuropsychiatric disorders (78)
Neuroscience (2241)
Neurotech (1)
NextGen: Class of 2026 (2157)
Non-profit (912)
Now hiring (36)
Obesity (381)
Opinion (132)
Ovarian cancer (146)
Pain (121)
Pancreatic cancer (186)
Parkinson's disease (285)
Partnered (14)
Patents (356)
Patient recruitment (424)
Peanut (46)
People (29479)
Pharmaceutical (42)
Pharmacy benefit managers (10)
Phase 1 (16323)
Phase 2 (21705)
Phase 3 (14150)
Pipeline (4666)
Policy (98)
Postmarket research (992)
Preclinical (6843)
Press Release (32)
Prostate cancer (174)
Psychedelics (51)
Radiopharmaceuticals (261)
Rare diseases (781)
Real estate (1902)
Recruiting (12)
Regulatory (11806)
Reports (23)
Research institute (1023)
Resumes & cover letters (20)
Rett syndrome (29)
RNA editing (22)
RSV (21)
Schizophrenia (138)
Series A (213)
Series B (155)
Service/supplier (1)
Sickle cell disease (86)
Special edition (19)
Spinal muscular atrophy (124)
Sponsored (16)
Startups (2221)
State (1)
Stomach cancer (7)
Supply chain (37)
Tariffs (18)
The Weekly (67)
Vaccines (390)
Venture capital (81)
Weight loss (200)
Women's health (37)
Worklife (2)
Date
Today (121)
Last 7 days (426)
Last 30 days (1695)
Last 365 days (18987)
2026 (4622)
2025 (19159)
2024 (21843)
2023 (23966)
2022 (30247)
2021 (31137)
2020 (26590)
2019 (18341)
2018 (13441)
2017 (15635)
2016 (13739)
2015 (16812)
2014 (12452)
2013 (9312)
2012 (9526)
2011 (9706)
2010 (9313)
Location
Africa (208)
Alabama (69)
Alaska (2)
Arizona (85)
Arkansas (6)
Asia (31545)
Australia (4613)
California (7845)
Canada (2143)
China (1005)
Colorado (273)
Connecticut (283)
Delaware (258)
Europe (47352)
Florida (1006)
Georgia (227)
Hawaii (2)
Idaho (17)
Illinois (453)
India (56)
Indiana (185)
Iowa (8)
Japan (408)
Kansas (86)
Kentucky (10)
Louisiana (12)
Maine (13)
Maryland (856)
Massachusetts (6305)
Michigan (122)
Minnesota (297)
Mississippi (3)
Missouri (36)
Montana (17)
Nebraska (6)
Nevada (48)
New Hampshire (21)
New Jersey (1952)
New Mexico (13)
New York (1985)
North Carolina (912)
North Dakota (6)
Northern California (3904)
Ohio (189)
Oklahoma (11)
Oregon (24)
Pennsylvania (1435)
Puerto Rico (9)
Rhode Island (28)
South America (282)
South Carolina (10)
Southern California (3123)
Tennessee (45)
Texas (1019)
United States (26247)
Utah (126)
Virginia (157)
Washington D.C. (38)
Washington State (638)
West Virginia (1)
Wisconsin (53)
326,497 Results for "enlivex therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
January 26, 2026
·
5 min read
Press Releases
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
March 25, 2026
·
5 min read
Press Releases
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
March 23, 2026
·
6 min read
Press Releases
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors
November 24, 2025
·
6 min read
Press Releases
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement
November 27, 2025
·
5 min read
Press Releases
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
December 4, 2025
·
5 min read
Press Releases
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
October 29, 2025
·
4 min read
Press Releases
YUVEZZI™ from Tenpoint Therapeutics, Ltd. Is Now Available Nationwide Across the United States
March 30, 2026
·
6 min read
Press Releases
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
September 10, 2025
·
5 min read
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Enlivex Therapeutics Ltd. is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m. ET.
June 20, 2024
·
4 min read
1 of 32,650
Next
